ARS Pharmaceuticals (SPRY) Stock Forecast, Price Target & Predictions
SPRY Stock Forecast
ARS Pharmaceuticals stock forecast is as follows: an average price target of $23.33 (represents a 44.55% upside from SPRY’s last price of $16.14) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
SPRY Price Target
The average price target for ARS Pharmaceuticals (SPRY) is $23.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $18.00. This represents a potential 44.55% upside from SPRY's last price of $16.14.
SPRY Analyst Ratings
According to 5 Wall Street analysts, ARS Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for SPRY stock is 1 'Strong Buy' (20.00%), 4 'Buy' (80.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ARS Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 19, 2024 | Josh Schimmer | Cantor Fitzgerald | $30.00 | $14.24 | 110.67% | 85.87% |
| Aug 12, 2024 | Strong Buy | Raymond James | $22.00 | $10.85 | 102.76% | 36.31% |
| Jul 25, 2024 | Ryan Deschner | Raymond James | $18.00 | $10.40 | 73.08% | 11.52% |
| Mar 05, 2024 | Roanna Ruiz | Leerink Partners | $18.00 | $8.65 | 108.09% | 11.52% |
| Dec 13, 2022 | - | Leerink Partners | $14.00 | $7.12 | 96.63% | -13.26% |
The latest ARS Pharmaceuticals stock forecast, released on Aug 19, 2024 by Josh Schimmer from Cantor Fitzgerald, set a price target of $30.00, which represents a 110.67% increase from the stock price at the time of the forecast ($14.24), and a 85.87% increase from SPRY last price ($16.14).
ARS Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 4 |
| Avg Price Target | - | $23.33 | $22.00 |
| Last Closing Price | $16.14 | $16.14 | $16.14 |
| Upside/Downside | -100.00% | 44.55% | 36.31% |
In the current month, the average price target of ARS Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ARS Pharmaceuticals's last price of $16.14. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 08, 2024 | Leerink Partners | Underperform | Underperform | Hold |
| Oct 08, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
| Sep 09, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
| Sep 09, 2024 | Dawson James | Underperform | Underperform | Hold |
| Aug 19, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Aug 12, 2024 | Raymond James | Outperform | Strong Buy | Upgrade |
| Jul 25, 2024 | Raymond James | - | Outperform | Initialise |
| Mar 05, 2024 | Leerink Partners | - | Outperform | Upgrade |
| Feb 20, 2024 | William Blair | Market Perform | Outperform | Upgrade |
| Sep 21, 2023 | William Blair | Outperform | Market Perform | Downgrade |
ARS Pharmaceuticals's last stock rating was published by Leerink Partners on Oct 08, 2024. The company gave SPRY a "Underperform" rating, the same as its previous rate.
ARS Pharmaceuticals Financial Forecast
ARS Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $67.56M | $87.02M | $57.14M | $35.55M | $21.10M | $19.57M | $11.35M | $4.65M | $4.06M | $575.00K | $1.00M | $1.00M |
| High Forecast | $67.56M | $87.02M | $57.14M | $35.55M | $21.10M | $19.57M | $11.35M | $4.65M | $4.06M | $575.00K | $1.00M | $1.00M |
| Low Forecast | $67.56M | $87.02M | $57.14M | $35.55M | $21.10M | $19.57M | $11.35M | $4.65M | $4.06M | $575.00K | $1.00M | $1.00M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
ARS Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. SPRY's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
ARS Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-27.37M | $-35.26M | $-23.15M | $-14.41M | $-8.55M | $-7.93M | $-4.60M | $-1.89M | $-1.64M | $-232.99K | $-405.19K | $-405.19K |
| High Forecast | $-27.37M | $-35.26M | $-23.15M | $-14.41M | $-8.55M | $-7.93M | $-4.60M | $-1.89M | $-1.64M | $-232.99K | $-405.19K | $-405.19K |
| Low Forecast | $-27.37M | $-35.26M | $-23.15M | $-14.41M | $-8.55M | $-7.93M | $-4.60M | $-1.89M | $-1.64M | $-232.99K | $-405.19K | $-405.19K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict SPRY's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ARS Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
ARS Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $23.92M | $36.22M | $15.69M | $1.64M | $-18.36M | $-24.50M | $-22.09M | $-25.10M | $-25.18M | $-13.78M | $-10.71M | $-9.58M |
| High Forecast | $23.92M | $36.22M | $15.69M | $1.64M | $-18.36M | $-24.50M | $-22.09M | $-25.10M | $-25.18M | $-13.01M | $-10.71M | $-9.58M |
| Low Forecast | $23.92M | $36.22M | $15.69M | $1.64M | $-18.36M | $-24.50M | $-22.09M | $-25.10M | $-25.18M | $-14.54M | $-10.71M | $-9.58M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
ARS Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SPRY's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ARS Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $21.48B | $27.67B | $18.17B | $11.31B | $6.71B | $6.22B | $3.61B | $1.48B | $1.29B | $182.83M | $317.96M | $317.96M |
| High Forecast | $21.48B | $27.67B | $18.17B | $11.31B | $6.71B | $6.22B | $3.61B | $1.48B | $1.29B | $182.83M | $317.96M | $317.96M |
| Low Forecast | $21.48B | $27.67B | $18.17B | $11.31B | $6.71B | $6.22B | $3.61B | $1.48B | $1.29B | $182.83M | $317.96M | $317.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
ARS Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to SPRY last annual SG&A of $NaN (undefined).
ARS Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $0.25 | $0.37 | $0.16 | $0.02 | $-0.19 | $-0.25 | $-0.23 | $-0.26 | $-0.26 | $-0.14 | $-0.11 | $-0.10 |
| High Forecast | $0.25 | $0.37 | $0.16 | $0.02 | $-0.19 | $-0.25 | $-0.23 | $-0.26 | $-0.26 | $-0.13 | $-0.11 | $-0.10 |
| Low Forecast | $0.25 | $0.37 | $0.16 | $0.02 | $-0.19 | $-0.25 | $-0.23 | $-0.26 | $-0.26 | $-0.15 | $-0.11 | $-0.10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, ARS Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SPRY previous annual EPS of $NaN (undefined).
ARS Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.75 | $70.00 | 9233.33% | Buy |
| INAB | IN8bio | $0.23 | $14.00 | 5986.96% | Buy |
| CUE | Cue Biopharma | $1.11 | $5.00 | 350.45% | Buy |
| CNSP | CNS Pharmaceuticals | $0.12 | $0.50 | 316.67% | - |
| IMMX | Immix Biopharma | $1.69 | $7.00 | 314.20% | Buy |
| DRMA | Dermata Therapeutics | $1.58 | $6.00 | 279.75% | Buy |
| TCRX | TScan Therapeutics | $5.26 | $12.00 | 128.14% | Buy |
| ANNX | Annexon | $7.63 | $14.00 | 83.49% | Buy |
| SPRY | ARS Pharmaceuticals | $16.13 | $23.33 | 44.64% | Buy |
| WVE | Wave Life Sciences | $14.61 | $20.17 | 38.06% | Buy |
| ZURA | Zura Bio | $4.89 | $5.00 | 2.25% | Buy |
| PALI | Palisade Bio | $3.57 | $1.50 | -57.98% | Buy |
SPRY Forecast FAQ
Is ARS Pharmaceuticals a good buy?
Yes, according to 5 Wall Street analysts, ARS Pharmaceuticals (SPRY) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of SPRY's total ratings.
What is SPRY's price target?
ARS Pharmaceuticals (SPRY) average price target is $23.33 with a range of $18 to $30, implying a 44.55% from its last price of $16.14. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ARS Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for SPRY stock, the company can go up by 44.55% (from the last price of $16.14 to the average price target of $23.33), up by 85.87% based on the highest stock price target, and up by 11.52% based on the lowest stock price target.
Can ARS Pharmaceuticals stock reach $20?
SPRY's average twelve months analyst stock price target of $23.33 supports the claim that ARS Pharmaceuticals can reach $20 in the near future.
What are ARS Pharmaceuticals's analysts' financial forecasts?
ARS Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $56.67M (high $56.67M, low $56.67M), average EBITDA is $-22.964M (high $-22.964M, low $-22.964M), average net income is $-90.051M (high $-90.051M, low $-90.051M), average SG&A $18.02B (high $18.02B, low $18.02B), and average EPS is $-0.93 (high $-0.93, low $-0.93). SPRY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $247.27M (high $247.27M, low $247.27M), average EBITDA is $-100M (high $-100M, low $-100M), average net income is $77.46M (high $77.46M, low $77.46M), average SG&A $78.62B (high $78.62B, low $78.62B), and average EPS is $0.8 (high $0.8, low $0.8).